Little Known Facts About ABBV-744 as a potential therapeutic option for aggressive cancers.
In Phase C, contributors will get ABBV-744 and oral navitoclax. In Section D, participants will obtain ABBV-744 and ruxolitinib. Contributors will receive treatment right up until illness progression or maybe the participants are not able to tolerate the study drugs.Over-all, our latest work highlights the potential utilization of ARV-825 in combin